Novo Nordisk A/S Net Income | NVO

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Novo Nordisk A/S

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
102 B	101 B	83.7 B	55.5 B	47.8 B	42.1 B	39 B	38.6 B	38.1 B	37.9 B	34.9 B	26.5 B	25.2 B	21.4 B	17.1 B

All numbers in DKK currency

Indicator range from annual reports

Maximum	Minimum	Average
102 B	17.1 B	47.4 B

Quarterly Net Income Novo Nordisk A/S

2025-Q4	2024-Q4	2023-Q4	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
102 B	101 B	83.7 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in DKK currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
102 B	83.7 B	95.7 B

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Nuvation Bio NUVB	-205 M	$ 4.95	1.07 %	$ 1.69 B	USA
Novavax NVAX	440 M	$ 12.56	20.08 %	$ 2.03 B	USA
Novartis AG NVS	14 B	$ 140.93	0.01 %	$ 273 B	Schweiz
NextCure NXTC	-55.8 M	$ 5.05	0.59 %	$ 14.4 M	USA
Ocugen OCGN	-68 M	$ 1.04	1.96 %	$ 325 M	USA
Ocular Therapeutix OCUL	-266 M	$ 7.25	4.17 %	$ 1.36 B	USA
Oragenics OGEN	-984 K	$ 0.49	1.25 %	$ 1.06 M	USA
Olema Pharmaceuticals OLMA	-162 M	$ 8.25	0.3 %	$ 718 M	USA
Omeros Corporation OMER	-3.35 M	$ 18.9	1.56 %	$ 1.2 B	USA
Oncolytics Biotech ONCY	-31.7 M	$ 0.6	1.21 %	$ 57.5 M	Canada
ORIC Pharmaceuticals ORIC	-129 M	$ 12.49	2.34 %	$ 1.1 B	USA
Oramed Pharmaceuticals ORMP	64 M	$ 4.55	1.34 %	$ 188 M	Israel
Outlook Therapeutics OTLK	-62.4 M	$ 0.6	0.42 %	$ 20.9 M	USA
Ovid Therapeutics OVID	-17.4 M	$ 2.34	0.21 %	$ 305 M	USA
Passage Bio PASG	-7.56 M	$ 4.09	0.73 %	$ 13.1 M	USA
Puma Biotechnology PBYI	31.1 M	$ 9.67	1.68 %	$ 484 M	USA
Processa Pharmaceuticals PCSA	-13.6 M	$ 1.49	0.62 %	$ 1.95 M	USA
Vaxcyte PCVX	-767 K	$ 73.82	30.7 %	$ 10 B	USA
PDS Biotechnology Corporation PDSB	-7.56 M	$ 1.2	60.32 %	$ 55.7 M	USA
Pfizer PFE	7.77 B	$ 27.41	0.02 %	$ 156 B	USA
Precigen PGEN	-251 M	$ 7.74	4.02 %	$ 2.42 B	USA
Pharming Group N.V. PHAR	33 M	$ 9.8	0.51 %	$ 6.75 B	Niderland
Phathom Pharmaceuticals PHAT	-221 K	$ 6.7	1.77 %	$ 489 M	USA
Phio Pharmaceuticals Corp. PHIO	-8.7 M	$ 0.99	0.6 %	$ 5.92 M	USA
Pliant Therapeutics PLRX	149 M	$ 1.03	0.48 %	$ 63.2 M	USA
Protalix BioTherapeutics PLX	-6.6 M	$ 2.71	0.37 %	$ 213 M	Israel
PMV Pharmaceuticals PMVP	-77.7 M	$ 1.78	2.29 %	$ 93.5 M	USA
Praxis Precision Medicines PRAX	-303 M	$ 283.56	3.0 %	$ 6.38 B	USA
PainReform Ltd. PRFX	-5.02 M	$ 0.88	0.04 %	$ 570 K	Israel
Prelude Therapeutics Incorporated PRLD	-99.5 M	$ 3.77	2.72 %	$ 290 M	USA
ProQR Therapeutics N.V. PRQR	-42.2 M	$ 1.67	2.14 %	$ 176 M	Niderland
Prothena Corporation plc PRTA	-244 M	$ 8.27	0.35 %	$ 445 M	USA
PTC Therapeutics PTCT	683 M	$ 63.65	0.3 %	$ 5.06 B	USA
Protagonist Therapeutics PTGX	-130 M	$ 140.63	0.41 %	$ 8.94 B	USA
Pulmatrix PULM	-1.17 M	$ 1.48	0.64 %	$ 5.41 B	USA
PolyPid Ltd. PYPD	-34.2 M	$ 5.2	0.19 %	$ 85 M	Israel
Repare Therapeutics RPTX	-84.7 M	-	-	$ 112 M	Canada
uniQure N.V. QURE	-199 M	$ 22.8	0.39 %	$ 1.31 B	Niderland
Rocket Pharmaceuticals RCKT	-223 M	$ 2.61	1.95 %	$ 290 M	USA
Arcus Biosciences RCUS	-353 M	$ 24.74	1.23 %	$ 2.66 B	USA
Regeneron Pharmaceuticals REGN	4.5 B	$ 726.47	0.05 %	$ 76 B	USA
Replimune Group REPL	-314 M	$ 13.15	0.61 %	$ 1.22 B	USA
Rafael Holdings RFL	-290 K	$ 1.47	0.65 %	$ 43.3 M	USA
REGENXBIO RGNX	-194 M	$ 7.76	4.44 %	$ 400 M	USA
Rigel Pharmaceuticals RIGL	367 M	$ 47.79	1.36 %	$ 860 M	USA
Relay Therapeutics RLAY	-276 M	$ 19.39	2.27 %	$ 3.33 B	USA
Avidity Biosciences RNA	-685 M	$ 7.97	1.66 %	$ 1.1 B	USA
Royalty Pharma plc RPRX	771 M	$ 56.66	0.36 %	$ 24.4 B	USA
Revolution Medicines RVMD	-1.13 B	$ 207.68	0.5 %	$ 39.5 B	USA